Journal of Lipid Research
Research ArticlesAlirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]
Cited by (0)
This work was supported by Sanofi-Aventis and Regeneron. J. W. Jukema received research grants from and was speaker on (CME-accredited) meetings sponsored by Amgen, Astellas, Astra-Zeneca, Biotronik, Boston Scientific, Daiichi Sankyo, Lilly, Genzyme, Medtronic, Merck-Schering-Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, Sanofi-Aventis, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands, and the European Community Framework KP7 Programme. W. J. Sasiela and V. Gusarova are employees of Regeneron. A. Peyman, H-L. Schäfer, and U. Schwahn are employees of Sanofi-Aventis.
- FH
familial hypercholesterolemia
- HPS
hematoxylin-phloxine-saffron
- ICAM-1
intercellular adhesion molecule 1
- LDL-C
LDL cholesterol
- LDLR
LDL receptor
- PCSK9
proprotein convertase subtilisin/kexin type 9
- SMC
smooth muscle cell
- TC
total cholesterol
Abbreviations:
- [S]
The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of four tables, one figure, Methods, and Results.
- 1
S. Kühnast and J. W. A. van der Hoorn contributed equally to this article.